CNTA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CNTA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2025-03-14), Centessa Pharmaceuticals's 6-1 Month Momentum % is 3.71%.
The industry rank for Centessa Pharmaceuticals's 6-1 Month Momentum % or its related term are showing as below:
For the Biotechnology subindustry, Centessa Pharmaceuticals's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Centessa Pharmaceuticals's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Centessa Pharmaceuticals's 6-1 Month Momentum % falls into.
6-1 Month Momentum % is calculated as following:
6-1 Month Momentum % | = | ( Price 1-month ago | / | Price 6-month ago | - 1 ) | * | 100 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Centessa Pharmaceuticals (NAS:CNTA) 6-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Thank you for viewing the detailed overview of Centessa Pharmaceuticals's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Iqbal J Hussain | officer: General Counsel | C/O CENTESSA PHARMACEUTICALS PLC, D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS, CAMBRIDGE X0 CB22 3FH |
Karen M. Anderson | officer: Chief People Officer | C/O MIMECAST LTD., 191 SPRING STREET, LEXINGTON MA 02421 |
Tia L Bush | officer: Chief Quality Officer | C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT |
Gregory M Weinhoff | officer: Chief Financial Officer | C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT |
Saurabh Saha | director, officer: Chief Executive Officer | C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT |
Harris Rotman | officer: SVP Regulatory Affairs | C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT |
Antoine Yver | officer: Chief Medical Officer | C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT |
David J Grainger | officer: Chief Innovation Officer | C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT |
Thomas Templeman | officer: Chief Technology Officer | C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT |
David M Chao | officer: Chief Administrative Officer | C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT |
Mathias Hukkelhoven | director | C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT |
Javad Shahidi | officer: Chief Medical Officer | C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT |
Medicxi Ventures Management (jersey) Ltd | 10 percent owner | C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG |
Rubertis Francesco De | director | C/O MEDICXI, COURS DE RIVE 10, GENEVA V8 CH-1204 |
Aaron Kantoff | director | C/O CENTESSA PHARMACEUTICALS PLC, D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS, CAMBRIDGE X0 CB22 3FH |
From GuruFocus
By Marketwired • 09-26-2024
By Marketwired • 08-21-2024
By GuruFocus Research • 02-06-2024
By Marketwired • 05-21-2024
By GuruFocus News • 10-26-2024
By GuruFocus Research • 03-27-2024
By Marketwired • 08-13-2024
By GuruFocus Research • 09-27-2024
By Marketwired • 09-13-2024
By GuruFocus Research • 02-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.